The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma.
 
Shishir K. Maithel
Research Funding - Celgene
 
Milind M. Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Amit Mahipal
Consulting or Advisory Role - AstraZeneca/MedImmune; QED Therapeutics; Taiho Oncology
Research Funding - Taiho Pharmaceutical
 
Bruce Shih-Li Lin
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Exelixis; Pfizer; QED Therapeutics
Research Funding - Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Incyte (Inst); Merck (Inst); Nucana (Inst); Sillajen (Inst); Zymeworks (Inst)
 
Mehmet Akce
Consulting or Advisory Role - AstraZeneca; Curio Science; Eisai; Exelixis; GlaxoSmithKline; Ipsen; Isofol Medical; QED Therapeutics
Research Funding - Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); IMPAC Medical Systems (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Polaris (Inst); RedHill Biopharma (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); Xencor (Inst)
 
Jeffrey M. Switchenko
No Relationships to Disclose
 
Manali Rupji
No Relationships to Disclose
 
Hop Tran Cao
No Relationships to Disclose
 
Sean P. Cleary
No Relationships to Disclose
 
Flavio G. Rocha
Consulting or Advisory Role - Medtronic
Research Funding - Gunze
Travel, Accommodations, Expenses - Lynx Group